rFGF4 alleviates lipopolysaccharide-induced acute lung injury by inhibiting the TLR4/NF-κB signaling pathway.
Wang X, Zhou L, Ye S, Liu S, Chen L, Cheng Z, Huang Y, Wang B, Pan M, Wang D, Wang L, Lei Z, Im YJ, Li X.
Wang X, et al. Among authors: pan m.
Int Immunopharmacol. 2023 Apr;117:109923. doi: 10.1016/j.intimp.2023.109923. Epub 2023 Feb 27.
Int Immunopharmacol. 2023.
PMID: 36842235